Sunday November 08 2009 | Biotechnology feed | All feeds
|
|
Sunday November 08 2009 | Biotechnology feed | All feeds
|
|
|
The launch of
sildenafil has heralded a mass of research aimed at identifying new targets
for both erectile dysfunction and the parallel female arousal disorder (click
here to visit our recent dossier on this subject). Likewise other sexual
dysfunctions are receiving increased attention. Premature ejaculation
represents a major market, and indeed in the age-range of 18-59 years old,
premature ejaculation represents the predominant sexual dysfunction affecting
28.5% of men. Today, there is no approved medical therapy for the treatment of
premature ejaculation and successful pharmaceutical development in this field
may therefore reap immense rewards. Selective serotonin reuptake inhibitors (SSRIs)
offer a treatment strategy, with, for example citalopram improving premature
ejaculation in over 60% of sufferers. Likewise sertraline has also provided
therapeutic benefit. This introduces a paradox however, since the SSRIs are
frequently associated with reduced desire and erectile dysfunction. The
concomitant use of SSRIs and sildenafil may therefore represent an appropriate
approach. Chen et al have
now taken this concept one step further showing that sildenafil may actually
improve the efficacy of paroxetine in treating premature ejaculation in
addition to overcoming its adverse effects. In 100 patients treated with
paroxetine alone, 42 reported improvement as determined by both a subjective
scoring system and intravaginal ejaculatory latency time. Of the remaining 58
patients, 56 that received a combination of paroxetine and sildenafil reported
improvement. The dual use of SSRIs and sildenafil may therefore offer a useful
approach to patients with premature ejaculation. An in depth evaluation of this field can be requested by clicking the request button above or scroll down for information on our CustomReport service. <Should this project be the subject of a full DiscoveryDossier? Click the request button above> Entry date March, 2003 Adapted from Chen et al, Urology 2003 Jan;61(1):197-200 - Interested in collaborating with this group? Contact LeadDiscovery or the authors direct.
Interested in collaborating with this group? Contact leaddiscovery@bioportfolio.co.uk Projects such as these are overviewed in full DiscoveryDossiers. LeadDiscovery and BioPortfolio aims to provide reliable, insightful analysis on the biotechnology industry. However, this information is provided "as is" and no representations or warranties either express or implied of completeness, accuracy, or of any other nature are made with respect to this information. This information is neither an offer to sell nor a solicitation to buy the securities of any company. This information contains forward-looking statements, which involve risks and uncertainties which may not be listed. The biotechnology industry is an emerging industry and the securities of the companies mentioned in this report have a very high degree of risk and volatility. For this reason, this information is supplied on the condition that the reader will make his or her own determination as to its suitability for any purpose prior to any use of this information. The employees and officers of LeadDiscovery and BioPortfolio may hold positions in some or all of the stocks discussed in this report. This abstract has been produced by LeadDiscovery Ltd. Founded by life scientists for life scientists we aim to help industry identify cutting edge drug discovery options and academic/biotech institutions maximize the potential of their research. Abstracts strictly reflect the opinion of LeadDiscovery's editorial panel. While all reasonable efforts are made to ensure the accuracy of information provided LeadDiscovery and the publisher BioPortfolio, takes no responsibility for incorrect or misleading information. LeadDiscovery is designed for educational and drug development purposes only and is not intended or designed to offer medical advice or advice of any sort, and must not be used for such purpose. The information provided through LeadDiscovery and BioPortfolio should not be used for diagnosing or treating a health problem or a disease and no reliance should be placed on any information contained in this abstract or elsewhere on LeadDiscovery's and BioPortfolio's website. It is not intended to be a substitute for professional care. If you have or suspect you may have a health problem, you should consult your physician or other health care provider. |
|
|
